Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Capital Markets

<ul><li>Eli Lilly had a strong quarter as the company went ahead expanding its new set of drugs worldwide and advancing its pipeline candidates in late-stage development while also building long-term opportunities through early-stage investments in technology and progress in early-stage programs.</li><li>Many of Eli Lilly’s pipeline candidates achieved significant milestones including FDA approval for Verzenio to be used for people with high-risk early breast cancer.</li><li>The company also continues to augment its pipeline with future development opportunities as it continues to leverage external innovation to build Eli Lilly's discovery capabilities with a focus on new modalities at Lilly.</li></ul>

Eli Lilly had a strong quarter as the company went ahead expanding its new set of drugs worldwide and advancing its pipeline candidates in late-stage development while also building long-term opportunities through early-stage investments in technology and progress in early-stage programs.Many of Eli Lilly’s pipeline candidates achieved significant milestones including FDA approval for Verzenio to be used for people with high-risk early breast cancer.The company also continues to augment its pipeline with future development opportunities as it continues to leverage external innovation to build Eli Lilly's discovery capabilities with a focus on new modalities at Lilly.

<ul><li>Eli Lilly & Company has witnessed a decent sequential top-line growth in the recent results driven by the strength of their underlying business as healthcare systems continue recovering from the pandemic.</li><li>Eli Lilly’s management intends to incorporate Protomer’s technology into its diabetes pipeline.</li><li>The management believes glucose-sensing might become the next generation solution for insulin treatment to improve the quality of life for people living with diabetes.</li></ul>

Eli Lilly & Company has witnessed a decent sequential top-line growth in the recent results driven by the strength of their underlying business as healthcare systems continue recovering from the pandemic.Eli Lilly’s management intends to incorporate Protomer’s technology into its diabetes pipeline.The management believes glucose-sensing might become the next generation solution for insulin treatment to improve the quality of life for people living with diabetes.

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Connect Biopharma / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/connect-biopharma-holdings-l" target="_blank" data-smartkarma-citation="entities:32187:1" rel="noopener">Connect Biopharma (CNTB US)</a> is a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell-driven inflammatory diseases. Connect has a pipeline of four drug candidates. The two most advanced clinical-stage programs, CBP-201 and CBP-307, are potentially differentiated product candidates against validated targets.</p><p>Connect has launched a Nasdaq IPO to raise net proceeds of $135 million at the mid-point of the IPO price range of $15.00 and $17.00 per ADS. At the mid-point of the IPO price range, Connect will command a market cap of $863 million.</p><div class="content-highlight"><p>Connect specialises in designing and developing product candidates that modulate the immune system, with a particular focus on T cells. CBP-201, the lead product candidate, has the potential to bring improved therapeutic benefit to atopic dermatitis (AD) patients than the current standard of care. CBP-307 has the potential to deliver best-in-class lymphocyte recovery times in combination with a well-tolerated safety profile for the treatment of UC (ulcerative colitis) and CD (Crohn’s disease). Overall, we believe that the prospects of Connect’s clinical-stage drug assets are favourable. We will discuss the rNPV of the assets in our next note.</p></div>

Connect Biopharma (CNTB US) is a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell-driven inflammatory diseases. Connect has a pipeline of four drug candidates. The two most advanced clinical-stage programs, CBP-201 and CBP-307, are potentially differentiated product candidates against validated targets.Connect has launched a Nasdaq IPO to raise net proceeds of $135 million at the mid-point of the IPO price range of $15.00 and $17.00 per ADS. At the mid-point of the IPO price range, Connect will command a market cap of $863 million.Connect specialises in designing and developing product candidates that modulate the immune system, with a particular focus on T cells. CBP-201, the lead product candidate, has the potential to bring improved therapeutic benefit to atopic dermatitis (AD) patients than the current standard of care. CBP-307 has the potential to deliver best-in-class lymphocyte recovery times in combination with a well-tolerated safety profile for the treatment of UC (ulcerative colitis) and CD (Crohn’s disease). Overall, we believe that the prospects of Connect’s clinical-stage drug assets are favourable. We will discuss the rNPV of the assets in our next note.

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Bottom-Up

<p>BeiGene has outlicensed ex-China rights to its PD-1 tislelizumab to Novartis on favorable terms, validating the competitive position of this compound in a crowded market. Further, the agreement marks a growing trend of Chinese companies outlicensing products to multinationals, which can have a leveraged benefit on their P&amp;Ls and valuations.</p>

BeiGene has outlicensed ex-China rights to its PD-1 tislelizumab to Novartis on favorable terms, validating the competitive position of this compound in a crowded market. Further, the agreement marks a growing trend of Chinese companies outlicensing products to multinationals, which can have a leveraged benefit on their P&amp;Ls and valuations.

BeiGene: Novartis Grabs Tislelizumab Rights

New Horizon Health  / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/new-horizon-health-limited" target="_blank" data-smartkarma-citation="entities:31039:1" rel="noopener">New Horizon Health (NHH HK)</a> is a leading player in China’s colorectal cancer screening market. It has two self-developed cancer screening tests - Pupu Tube and ColoClear. It will have a listing hearing for a $300 million Hong Kong IPO this week, according to press reports.</p><div class="content-highlight"><p>New Horizon is a play on the rapid growth of the cancer screening market in China, particularly the colorectal cancer screening market. Colorectal cancer is one of the deadliest cancer types in China, both by incidence and mortality rates. The colorectal cancer screening market in China is expected to grow significantly to be worth RMB19.8 billion in 2030 (18.7% CAGR between 2019 to 2030) due to the availability of more effective screening solutions and increased awareness of cancer screening, according to Frost &amp; Sullivan. We believe that New Horizon has the right ingredients to capitalise on this market opportunity. </p></div>

New Horizon Health (NHH HK) is a leading player in China’s colorectal cancer screening market. It has two self-developed cancer screening tests - Pupu Tube and ColoClear. It will have a listing hearing for a $300 million Hong Kong IPO this week, according to press reports.New Horizon is a play on the rapid growth of the cancer screening market in China, particularly the colorectal cancer screening market. Colorectal cancer is one of the deadliest cancer types in China, both by incidence and mortality rates. The colorectal cancer screening market in China is expected to grow significantly to be worth RMB19.8 billion in 2030 (18.7% CAGR between 2019 to 2030) due to the availability of more effective screening solutions and increased awareness of cancer screening, according to Frost &amp; Sullivan. We believe that New Horizon has the right ingredients to capitalise on this market opportunity. 

New Horizon Health IPO Initiation: Screening for Cancer

United States

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Eli Lilly & (LLY UN)

Eli Lilly & Company - Investment Thesis

Eli Lilly had a strong quarter as the company went ahead expanding its new set of drugs worldwide and advancing its pipeline candidates in...

Baptista Research

Eli Lilly & Company - Investment Thesis

Eli Lilly & Company has witnessed a decent sequential top-line growth in the recent results driven by the strength of their underlying...

Baptista Research

Connect Biopharma IPO: Potent Medicine

Connect has launched a Nasdaq IPO to raise net proceeds of $135m at the mid-point of the IPO price range. Overall, we believe that the prospects of...

Arun George

BeiGene: Novartis Grabs Tislelizumab Rights

BeiGene's deal with Novartis for PD-1 tislelizumab validates its competitive position, and marks a rising trend of Chinese companies licensing...

Kemp Dolliver, CFA

New Horizon Health IPO Initiation: Screening for Cancer

New Horizon will have a listing hearing for a $300 million HK IPO this week. We believe that New Horizon has the right ingredients to capitalise on...

Arun George

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)